Skip to main content
Log in

Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

In COPD, the systemic effects of the disease reflect the structural and/or biochemical alterations occurring in the structures or organs other than the lungs in relation to the characteristics of the primary disease. The disorders of endothelial structures due to COPD may lead vascular pathologies, such as ischemic heart disease, stroke, to occur more commonly in those with COPD. On consideration of the fact that the vascular endothelium is a major site in which the systemic effect of the inflammation occurs, should von Willebrand Factor, a clotting factor of endothelium origin, and the plasma level of fibrinogen vary with the severity of the disease in COPD, the variability of arterial blood gas values, and the stability or exacerbation of the disease? Considering the fact that microalbuminuria is an indirect manifestation of the renal endothelial permeability and/or renal perfusion; should there be an association between microalbuminuria and the severity of COPD? Therefore, in order to assess the effect of the systemic inflammation in COPD on the vascular endothelium, we compared the levels of the plasma vWF, fibrinogen, 24-h urine microalbuminuria of those with stable COPD (33 patients) and exacerbation of COPD (26 patients) with those of the controls (16 healthy subjects). The mean age was 63.42 ∓ 10.29, 68.00 ∓ 9.77 and 59.63 ∓ 14.10 years in SCOPD, COPDAE, and CG, respectively. The level of microalbuminuria was found to increase significantly in COPDAE group, compared to that of the controls (P = 0.004). When we investigated the relation between smoking burden and microalbuminuria, vWF, fibrinogen levels, the amount of consumption and positive relationship were found significant. (r = 0.336, P = 0.003 between smoking pack-years and vWF, r = 0.403, P = 0.001 between smoking pack-years and fibrinogen, and r = 0.262, P = 0.02 between smoking pack-years and microalbuminuria). The levels of vWF and fibrinogen are AECOPD > SCOPD > CG, with the highest being in AECOPD, and the difference among the groups was statistically significant. The relationship between the level of hypoxemia and microalbuminuria, fibrinogen and vWF was found to be significant (r = −0.360, P = 0.005 between oxygen saturation and microalbuminuria, r = −0.359, P = 0.005 between the level of PaO2 and fibrinogen, and r = −0.336, P = 0.009 between PaO2 and vWF). In conclusion, the levels of plasma vWF, fibrinogen, and microalbuminuria may be helpful in grading the severity of COPD exacerbation. The related increase in these markers may represent a possible pathophysiological mechanism behind the increased vascular morbidity of patients with COPD and detecting indirectly the endothelial dysfunction as a manifestation of systemic outcomes due to COPD and in detecting earlier the cases in which the risk for developing the associated complications are higher. We suggest that further studies are necessary to investigate the impact of antithrombotic treatment on microalbuminuria, plasma vWF and fibrinogen as markers of endothelial dysfunction coexisting COPD exacerbation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Report. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2006. http://www.goldcopd.com)

  2. Gan WQ, Man SFP, Senthilselvan A, Sin DD (2004) Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax 59:574–580

    Article  PubMed  CAS  Google Scholar 

  3. Agusti AGN, Jones PW (2006) Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 27:822–827

    Article  PubMed  Google Scholar 

  4. Cines DB, Pollak ES, Buck CA et al (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527–3561

    PubMed  CAS  Google Scholar 

  5. Sin DD, Anthonisen NR, Soriano JB, Agusti AG (2006) Mortality in COPD: role of comorbidities. Eur Respir J 28:1245–1257

    Article  PubMed  CAS  Google Scholar 

  6. Paisley KE, Beaman M, Tooke JE et al (2003) Endothelial dysfunction and inflammation in asymtomatic proteinuria. Kidney Int 63:624–633

    Article  PubMed  Google Scholar 

  7. Becattini C, Agnelli G (2002) Pathogenesis of venous thromboembolism. Curr Opin Pulm Med 8(5):360–364

    Article  PubMed  Google Scholar 

  8. Lopes AA, Maeda N, Bydlowski S (1998) Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension. Am J Med 105:21–26

    Article  PubMed  CAS  Google Scholar 

  9. Blann AD (1991) Increased circulating levels of von Willebrand factor antigen in smokers may be due to lipid peroxides. Med Sci Res 19:535–536

    Google Scholar 

  10. Kannel WB, Wolf PA, Castelli WP et al (1987) Fibrinogen and risk of cardiovascular disease. JAMA 258:1183–1186

    Article  PubMed  CAS  Google Scholar 

  11. American Thoracic Society (1995) Standardization of spirometry. Am J Respir Crit Care Med 152:1107–1136

    Google Scholar 

  12. Autospiro Pal (1994) Operating instructions [product information]. Minato Medical Science Company Ltd, Osaka, Japan, pp 1–37

  13. Hansen JM, Olsen NV, Feldt-Rasmussen B et al (1994) Albuminuria and overall capillary permeability of albumin in acute altitude hypoxia. J Appl Physiol 76(5):1922–1927

    PubMed  CAS  Google Scholar 

  14. Gogo A, Ciaccia A, Legorini C et al (2003) Proteinuria in COPD patients with and without respiratory failure. Chest 123:652–653

    Article  Google Scholar 

  15. Sklar AH, Chaudhary BA (1988) Reversible proteinuria in obstructive sleep apnea syndrome. Arch Intern Med 148:87–89

    Article  PubMed  CAS  Google Scholar 

  16. Kilburn K, Dowell A (1971) Renal function in respiratory failure. Effects of hypoxia, hyperoxia,and hypercapnia. Arch Intern Med 127:754–762

    Article  PubMed  CAS  Google Scholar 

  17. Kömürcüoglu A, Kalenci S, Kalenci D, et al (2002) Kronik obstrüktif akciğer hastalığında mikroalbüminüri. Toraks Dergisi 31–34 (In Turkish)

  18. Casserly LF, Chow N, Ali S et al (2001) Proteinuria in obstructive sleep apnea. Kidney Int 60:1484–1489

    Article  PubMed  CAS  Google Scholar 

  19. Pinto-Sietsma S, Mulder J, Janssen W et al (2000) Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 133:585–591

    PubMed  CAS  Google Scholar 

  20. Szakmany T, Molnar Z (2004) Increased glomerular permeability and pulmonary dysfunction following major surgery: correlation of microalbuminuria and PaO2/FiO2 ratio. Acta Anaesthesiol Scand 48:704–710

    Article  PubMed  CAS  Google Scholar 

  21. Pontremoli R, Nicolella C, Viazzi F et al (1998) Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J hypertens 11:430–438

    Article  PubMed  CAS  Google Scholar 

  22. Hillege H, Fidler V, Gilles P et al (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782

    Article  PubMed  CAS  Google Scholar 

  23. Hirano T, Ookubo K, Kashiwazaki K et al (2000) Vascular endothelial markers, von willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy:comparison of primary renal disease. Clin Chim Acta 299:65–75

    Article  PubMed  CAS  Google Scholar 

  24. Jensen J, Myrup B, Borch-Johnsen K et al (1995) Aspects of haemostatic function in healthy subjects with microalbuminuria. A potential atherosclerotic risk factor. Thromb Res 77:423–430

    Article  PubMed  CAS  Google Scholar 

  25. Rosemberg RD, Bauer KA (1994) The heparin antithrombin system: a natural anticoagluant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Haemostasis and thrombosis: basic principles and clinical practice. Lippincott, Philadelphia, pp 837–860

    Google Scholar 

  26. Mannucci PM (1998) Von Willebrand Factor: A marker of endothelial damage? Arterioscler Thromb Vasc Biol 18:1359–1362

    PubMed  CAS  Google Scholar 

  27. McGill S, Ahmed N, Christou N (1998) İncreased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation. Crit Care Med 26:296–300

    Article  PubMed  CAS  Google Scholar 

  28. Kannel WB, D’Agostino R, Belanger AJ (1987) Fibrinogen, cigarette smoking and risk of cardiovascular disease: insights from the Framingham study. Am Heart J 113:1006–1010

    Article  PubMed  CAS  Google Scholar 

  29. Maat MPM de, Pietersma A, Kofflard M et al (1996) Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 121:185–191

    Article  PubMed  Google Scholar 

  30. Dahl M, Hansen AT, Vestbo J et al (2001) Elevated plasma fibrinogen associated with reduced pulmonary function and increased Risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:1008–1011

    PubMed  CAS  Google Scholar 

  31. Boldy DA, Short PE, Cowen P et al (1998) Plasma levels of von Willebrand Factor antigen in acute bronchitis and in a normal population. Respir Med 92:395–400

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mehmet Polatli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polatli, M., Çakir, A., Cildag, O. et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 26, 97–102 (2008). https://doi.org/10.1007/s11239-007-0073-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-007-0073-1

Keywords

Navigation